Atezolizumab

證據等級: L5

預測適應症: 10 個

Atezolizumab: From Bladder Urothelial Carcinoma to Prostatic Urethra Urothelial Carcinoma

One-Sentence Summary

Atezolizumab is a PD-L1 checkpoint inhibitor immunotherapy globally approved for multiple cancers including urothelial carcinoma, though it currently holds no Taiwan marketing authorization. The TxGNN model predicts it may be effective for Prostatic Urethra Urothelial Carcinoma as its top-ranked new indication, with 2 clinical trials supporting this direction through biological equivalence with anatomically adjacent urothelial carcinoma subtypes.

Quick Overview

Item	Content
Original Indication	No Taiwan-registered indications (globally: urothelial carcinoma, NSCLC, TNBC, hepatocellular carcinoma)
Predicted New Indication	Prostatic Urethra Urothelial Carcinoma
TxGNN Prediction Score	99.98%
Evidence Level	L2
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from DrugBank is not available (Data Gap DG002). Based on established clinical knowledge, Atezolizumab is a humanised monoclonal antibody that selectively binds PD-L1 (Programmed Death-Ligand 1), blocking its interaction with both PD-1 and B7.1 receptors. This restores cytotoxic T-cell activity within the tumour microenvironment. The mechanism is particularly potent in tumours with high PD-L1 expression — a hallmark of the urothelial carcinoma family regardless of anatomical site.

Prostatic urethra urothelial carcinoma is an anatomical subsite within the urothelial carcinoma spectrum. Bladder urothelial carcinoma and prostatic urethral involvement share identical cellular origin (transitional epithelium), equivalent PD-L1 overexpression profiles, and frequently co-exist in non-muscle invasive bladder cancer (NMIBC). The prostatic urethra is one of the most common sites of NMIBC extension, meaning the BCG-unresponsive NMIBC population studied in Phase 2 (NCT02844816) very likely included patients with prostatic urethral disease.

The combination of a completed Phase 2 trial in the directly adjacent disease population, near-perfect TxGNN prediction score (99.98%), and mechanistic equivalence across the urothelial carcinoma family makes this prediction biologically sound. The primary uncertainty is not biological plausibility but rather the absence of a trial specifically enrolling prostatic urethra urothelial carcinoma as a defined endpoint.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02844816	Phase 2	Completed	172	Atezolizumab monotherapy in BCG-unresponsive recurrent/refractory NMIBC; immunotherapy may help the body’s immune system attack cancer and interfere with tumour cell growth and spread
NCT03170960	Phase 1b	Active, Not Recruiting	914	Cabozantinib ± atezolizumab in multiple solid tumours including advanced urothelial carcinoma (bladder, renal pelvis, ureter, urethra), RCC, CRPC, NSCLC, TNBC, and ovarian cancer; safety, tolerability, preliminary efficacy and pharmacokinetics assessment

Literature Evidence

Currently no related literature available for Prostatic Urethra Urothelial Carcinoma.

Taiwan Market Information

Atezolizumab currently has no marketing authorization in Taiwan (0 registered licenses). No approved product records are available from TFDA. Please refer to the originator’s (Roche/Genentech) global SmPC (Tecentriq) for complete product information.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy — PD-L1 Checkpoint Inhibitor (monoclonal antibody; non-cytotoxic)
Myelosuppression Risk	Low (immune-mediated haematological events are uncommon; not associated with the typical myelosuppression of conventional cytotoxics)
Emetogenicity Classification	Minimal (not associated with clinically significant emetogenicity)
Monitoring Items	Liver function tests (ALT/AST/bilirubin), thyroid function (TSH, free T4), adrenal function, fasting glucose, CBC with differential, urinalysis; close monitoring for immune-related adverse events (irAEs) across all organ systems
Handling Protection	Standard biological/monoclonal antibody handling precautions apply; full cytotoxic drug handling protocols are not required

Safety Considerations

Detailed TFDA prescribing information is not yet available (Data Gap DG001 — Blocking). Please refer to the global Tecentriq SmPC for complete safety data.

Based on the drug class (PD-L1 checkpoint inhibitor), clinically important immune-related adverse events (irAEs) to anticipate include:

Immune-mediated pneumonitis — potentially life-threatening; monitor for new or worsening respiratory symptoms
Immune-mediated colitis — diarrhoea and abdominal pain; grade 3–4 events require corticosteroid management
Immune-mediated hepatitis — ALT/AST elevation; liver function monitoring required before each cycle
Endocrinopathies — hypothyroidism, hyperthyroidism, adrenal insufficiency, and diabetes mellitus (type 1-like)
Infusion-related reactions — typically grade 1–2; pre-medication protocols per institutional policy

Predicted Indications Overview (All 10)

Rank	Disease	TxGNN Score	Evidence Level	Decision
1	Prostatic Urethra Urothelial Carcinoma	99.98%	L2	Proceed with Guardrails
2	Kidney Pelvis Sarcomatoid Transitional Cell Carcinoma	99.98%	L4	Research Question
3	Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant	99.98%	L4	Research Question
4	Renal Pelvis Papillary Urothelial Carcinoma	99.98%	L3	Research Question
5	Uterine Ligament Adenocarcinoma	99.93%	L5	Hold
6	Endocervical Carcinoma	99.92%	L2	Proceed with Guardrails
7	Adenoid Cystic Carcinoma of the Cervix Uteri	99.92%	L5	Hold
8	Uterine Ligament Serous Adenocarcinoma	99.92%	L5	Hold
9	Signet Ring Cell Variant Cervical Mucinous Adenocarcinoma	99.91%	L5	Hold
10	Intestinal Variant Cervical Mucinous Adenocarcinoma	99.91%	L5	Hold

Note on Rank 6 (Endocervical Carcinoma): This indication also reaches L2, supported by a completed Phase 2 trial (NCT02921269, atezolizumab + bevacizumab in recurrent cervical cancer, n=11) and a completed Phase 1 trial (NCT03738228, atezolizumab + chemoradiotherapy, n=40). HPV-associated high tumour mutational burden and PD-L1 overexpression in endocervical carcinoma provide mechanistic rationale. Key limitation: the Phase 2 sample size (n=11) is very small.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The top prediction (Prostatic Urethra Urothelial Carcinoma, L2) is supported by a completed Phase 2 trial in BCG-unresponsive NMIBC — a population in which prostatic urethral involvement is a defining clinical feature — and a large Phase 1b basket trial covering the entire urothelial tract. Atezolizumab’s PD-L1 blocking mechanism is biologically uniform across the urothelial carcinoma family. Endocervical carcinoma (Rank 6) independently reaches L2 through direct HPV-related immunological rationale and dedicated cervical cancer trials.

To proceed, the following is needed:

Safety data gap (Blocking): Obtain TFDA SmPC or global SmPC (Tecentriq) to complete contraindication and warning assessment before any S1 safety evaluation
MOA data gap (High): Retrieve complete DrugBank MOA record (DB11595) to finalise mechanistic link scoring
Taiwan regulatory pathway: Assess feasibility of Taiwan NDA filing or compassionate use pathway, given current zero-license status
Prostatic urethra–specific evidence: Initiate or identify a dedicated clinical trial or registry study enrolling prostatic urethra urothelial carcinoma as a defined patient population
Sarcomatoid variants (Ranks 2–3): Collect PD-L1 expression and EMT biomarker data in sarcomatoid urothelial subtypes before escalating from L4 to a clinical development stage
Endocervical carcinoma (Rank 6): Validate in a larger Phase 2 cohort; the existing n=11 Phase 2 trial is underpowered for definitive conclusions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.